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Intensive research in recent years has begun to unlock the mysteries surrounding the molecular pathogenesis of melanoma, the
deadliest of skin cancers. The high-penetrance, low-frequency susceptibility gene CDKN2A produces tumor suppressor proteins
that function in concert with p53 and retinoblastoma protein to thwart melanomagenesis. Aberrant CDKN2A gene products
have been implicated in a great many cases of familial cutaneous melanoma. Sporadic cases, on the other hand, often involve
constitutive signal transduction along the mitogen-activated protein kinase (MAPK) pathway, with particular focus falling upon
mutatedRASandRAFprotooncogenes.TheproliferativeeﬀectsoftheMAPKpathwaymaybecomplementedbytheantiapoptotic
signals of the PI3K/AKT pathway. After skin, melanoma most commonly aﬀects the eye. Data for the constitutive activation of the
MAPK pathway in uveal melanoma exists as well, however, not through mutations of RAS and RAF. Rather, evidence implicates
the proto-oncogene GNAQ. In the following discussion, we review the major molecular pathways implicated in both familial
and sporadic cutaneous melanomagenesis, the former accounting for approximately 10% of cases. Additionally, we discuss the
molecular pathways for which preliminary evidence suggests a role in uveal melanomagenesis.
1.Introduction
Melanoma remains a disproportionate cause of death among
skin cancers [1, 2]. Currently, early diagnosis followed by
complete surgical removal of the tumor oﬀers the best hope
for cure [3]. Once advanced, melanoma is notoriously resis-
tant to medical interventions [3]. Thus, great interest lies in
the discovery of new therapeutic options that may improve
the prognoses of those aﬄicted with this unforgiving disease.
New insights into the development and/or progression
of cutaneous melanoma have been achieved through the
study of its molecular pathogenesis. Key molecules at crucial
junctions have been identiﬁed and have begun serving as
potential targets for clinicians tasked with containing this
lethal disease.
After skin, primary melanoma most commonly aﬀects
the eye [4]. The two most commonly employed modalities
for the treatment of uveal melanoma, the most lethal of
ocular melanomas, are radiation therapy and enucleation
[5]. Despite these valiant eﬀorts at local disease control, up
to 50% of patients succumb to their disease, and impact on
patient survival remains questionable at best [6]. Thus, a
great need for improved therapy exists for the treatment of
uveal melanoma.
In the following discussion, we review the major molec-
ular pathways implicated in both familial and sporadic
cutaneous melanomagenesis, the former accounting for
approximately 10% of cases [7]. Additionally, we discuss the
molecular pathways for which preliminary evidence suggests
a role in uveal melanomagenesis.
2.FamilialCutaneousMelanoma
Knowledge of some of the earliest molecular pathways
involved in melanomagenesis derived from investigations of
familialcutaneousmelanoma.Inaﬀectedindividuals,acom-
plex network of interrelated pathways functions to promote
cellular proliferation and cellular survival.
2.1. CDKN2A. The best-characterized high-penetrance sus-
ceptibility gene predisposing to cutaneous melanoma is
CDKN2A [3, 8–12]. This gene is located on chromosome2 Pathology Research International
9p21 and encodes two distinct tumor-suppressor proteins—
p14/ARF and p16/INK4a—implicated in the pathogenesis of
25–40% of familial cutaneous melanomas (Figure 1)[ 3, 13].
The former deters melanomagenesis through its indirect
eﬀect on p53, a tumor-suppressor protein also known as
“the guardian of the genome.” Upon sensing DNA damage,
p53 promotes the transcription of numerous genes involved
in cell cycle arrest and/or apoptosis. Simply stated, if DNA
damage can be repaired during cell cycle arrest, the cell
returns to its normal functional state. If damage is irrepara-
ble, however, p53 stimulates the transcription of microRNAs
(miRNAs), speciﬁcally the mir34 family of miRNAs, which
silence the translation of proproliferative and antiapoptotic
transcriptsresultingineitherquiescence/senescenceorapop-
tosis, respectively.
Underhomeostaticconditions,p53maintainsarelatively
short half-life due to the function of human homolog of
murine Mdm2 (HDM2), a protein that ubiquitinates other
proteins for destruction. When the cell is stressed, however,
p14/ARF binds to and inhibits the function of HDM2
allowing p53 to escape ubiquitination. Mutated p14/ARF,
on the other hand, is unable to bind and suppress HDM2,
allowing it to mark p53 for destruction. With less p53 avail-
able to identify damaged DNA, genomic instability results,
predisposing the aﬄicted individual to the development of
cutaneous melanoma.
p16/INK4a functions in concert with retinoblastoma
protein (RBp), another tumor-suppressor protein, to regu-
late the Gap 1 (G1) phase of the cell cycle. During this phase,
cells can exit the cell cycle into quiescence or senescence,
or make the necessary preparations to progress onward
into the S phase of the cycle. Speciﬁcally, phosphorylation
of RBp, which is partly dependent upon the cyclin D—
CDK4/6 complex, is necessary for the transcription of
genes encoding cyclin E, a protein that is required for the
initiation of DNA replication in the S phase. p16/INK4a
inhibits the phosphorylation of RBp by inactivating the
cyclin D—CDK4/6 complex and consequently prevents the
cell progression through the cell cycle. When p16 expression
is compromised, and so is RBp’s regulatory control on the
cell cycle.
2.2. CDK4. Linkage studies have allowed the identiﬁcation
of another high-penetrance, low-frequency melanoma sus-
ceptibility gene, CDK4, which is mutated in three cutaneous
melanoma kindreds worldwide [3, 9–11]. Located on chro-
mosome 12q14, CDK4 encodes cyclin-dependent kinase 4
protein, a constituent of the CDK4/6 complex discussed
above (Figure 1). Germline mutations that activate this gene
occur at codon 24 (Arg24Cys and Arg24His) and render the
CDK4/6 complex resistant to p16 inhibition. Similar to the
caseofaberrationsintheCDKN2Agene,mutationsinCDK4
lend to an increased risk for cutaneous melanomagenesis.
3. SporadicCutaneousMelanoma
3.1. RAS/RAF/MEK/ERK Signaling Pathway. Constitutive
stimulation of the mitogen-activated protein kinase (MAPK)
pathway, which regulates cellular proliferation, has been
implicated in up to 90% of cutaneous melanomas [3, 9, 11,
12, 14, 15]. The MAPK pathway exerts its eﬀects through
signal transduction along the cascade of RAS, RAF, MAPK
extracellular signal-regulated kinase (MEK), and extracel-
lular signal-regulated kinase (ERK) (Figure 2). MAPK sig-
naling initiates when a receptor tyrosine kinase in the cell
membrane binds its respective ligand—an event that results
in the activation of RAS, a membrane-bound protein with
GTPase activity. Activated RAS then recruits RAF, a cytoso-
lic serine-threonine-speciﬁc protein kinase, to the plasma
membrane. Through phosphorylation, RAS activates RAF,
which in turn phosphorylates and activates MEK. Activated
MEK activates ERK, which induces several proliferative and
survival processes, one of which is activation of the cyclin
D-CDK4/6 complex (discussed above) upon translocation to
the nucleus.
3.1.1. c-KIT. c-KIT, a protooncogene that encodes the type
III receptor tyrosine kinase KIT, was ﬁrst identiﬁed in 1987
as a result of sequence similarity to the Hardy-Zuckerman
4 feline sarcoma virus oncogene, v-KIT [16]. Upon binding
its ligand, stem cell factor (SCF), KIT undergoes receptor
dimerization, autophosphorylation, and activation of its
intracellular tyrosine kinase domain [8, 17]. Once activated,
KIT is capable of stimulating downstream signaling path-
w a y s ,s u c ha sM A P K[ 8, 17, 18].
Activating mutations and/or gene ampliﬁcation of KIT
are now being described in signiﬁcant subsets of melanomas
[19–23]. One study, in particular, recognized such aber-
rations in 39% of mucosal melanomas, 36% of acral
melanomas, and 28% of melanomas arising in chronically
sun-damaged skin (as deﬁned by the presence of solar elas-
tosis on review of histopathology)—anatomic sites at which
BRAF mutations occur far less frequently [22].
The most prevalent KIT mutations are L576P (exon 11),
K642E (exon 13), V559A (exon 11), and D816H (exon 17)
[17, 24]. These mutations are thought to promote the consti-
tutiveactivationofKITeitherthroughprecludingtheprotein
from assuming its default autoinhibited conformation, or by
promoting its dimerization in the absence of SCF [25, 26].
The precise manner in which constitutive KIT activation
promotes melanomagenesis remains unclear.
3.1.2. NRAS. First implicated in sarcoma in rats, HRAS and
KRAS—members of the RAS family of protooncogenes—
were recognized for their ability to undergo activating trans-
formation under the inﬂuence of the Harvey and Kirsten
sarcoma viruses. A third member of the RAS family, NRAS,
was subsequently identiﬁed in human neuroblastoma cells.
Of these three protooncogenes, activating mutations in
NRAS occur most frequently in melanocytes and have been
identiﬁed in nearly one-third of all melanomas [3, 12,
15]. The most commonly documented NRAS aberration in
melanomaisamissensemutationatcodon61(Q61R),which
results in the substitution of arginine in place of glutamine
and impairs GTP hydrolysis locking the protein in a state
of constitutive activation [27]. In comparison to other solid
tumors, mutations in RAS do not occur with as high as
a frequency in melanoma [3]. Nonetheless, in the absence ofPathology Research International 3
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Figure 1: Roles of p14/ARF, p16(INK4A), and cyclin-dependent kinase 4 protein in cellular proliferation and survival. Loss of function of
any of these molecules has been implicated in the pathogenesis of Familial Cutaneous Melanoma.
the inhibitory eﬀects of p16/INK4a, oncogenic RAS has been
shown to induce melanoma and appears to have an integral
function in tumor maintenance and progression [28, 29].
3.1.3.BRAF. EachofthethreeRAFprotooncogenes—ARAF,
BRAF,a n dCRAF—have been identiﬁed in mammals. While
ARAF and CRAF mutations are rare in human cancers, a sig-
niﬁcant percentage of human malignancies have been shown
to harbor activating mutations in BRAF, with the highest
rate occurring in melanoma [3, 9, 11, 12]. BRAF mutations
in melanoma tend to occur at anatomic sites exposed to
intermittent, rather than chronic, sun damage. With approx-
imately 70% of cases harboring such a mutation, BRAF is
the most commonly mutated protooncogene in cutaneous
melanoma. Furthermore, a signiﬁcant proportion of both
benign and dysplastic melanocytic nevi have been shown to
harbormutationofBRAF aswell,suggestingarelativelyearly
event in melanomagenesis [3, 11, 12, 30].
Greaterthan90%ofBRAF mutationsinmelanomaresult
from a single base missense mutation (T→A) at codon
1799 that leads to the substitution of valine in favor of
glutamic acid at position 600 of the BRAF protein [31]. This
alteration introduces a conformational change in BRAF’s
kinase domain, which can lead to a 480-fold increase in
kinase activity when compared to that of wild-type BRAF
[32]. However, the story is not as simple as this may suggest.
While mutated BRAF induces uncontrolled proliferation in
melanoma,itlendstosenescenceinbenignmelanocyticnevi.
Furthermore, a subset of melanocytes is able to bypass the
senescent response and undergo malignant transformation
upon the accumulation of additional insults.
3.2. PI3K/AKT Signaling Pathway. Activated RAS also trig-
gers the phosphatidylinositol 3-kinase (PI3K)/AKT pathway,
which conducts antiapoptotic signals that complement the
proliferative eﬀects of the MAPK pathway (Figure 2)[ 3,
11, 12, 15]. PI3K phosphorylates phosphatidylinositols of
the cell membrane to produce phosphatidylinositol-3,4,5-
triphosphate (PIP3). PIP3 then recruits the serine/threonine
kinase AKT, also known as protein kinase B, to the cell
membrane. Activation of AKT requires phosphorylation by
PDK1,2. AKT then promotes cell survival by phosphory-
lating several substrates, such as BAD (a member of the
bcl-2 family of apoptosis regulator proteins) and HDM2
(discussed above). AKT also inactivates the complex formed
by TSC1 and TSC2, tumor-suppressor proteins known to
be mutated in tuberous sclerosis. Inactivation of the TSC1/
TSC2 complex stimulates activity of mammalian target of
rapamycin (mTOR), a kinase that promotes the uptake of
nutrients necessary for cellular growth.
3.2.1. PTEN. The phosphatase and tensin homolog (PTEN)
gene is located on chromosome 10 and encodes a tumor-
suppressor protein that functions as both a lipid and protein
phosphatase [3, 11, 12, 15]. Speciﬁcally, the PTEN protein
degrades the products of PI3K, thereby antagonizing the
activity of the PI3K/AKT pathway. This results in increased
apoptosis and decreased tumorigenesis. Loss of functional
PTEN protein has been demonstrated in approximately 20%
of primary cutaneous melanomas and has been shown to
positively correlate with increasing Breslow thickness [33].
Frequency of mutations and deletions only partly account
for PTEN loss in melanoma samples, suggesting epigenetic4 Pathology Research International
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Figure 2: MAPK and PI3K/AKT pathways regulate cellular proliferation and survival. Aberrant functioning of these pathways has been
implicated in the pathogenesis of sporadic cutaneous melanoma.
mechanisms [34]. PTEN losses occur with greater fre-
quency in primary melanomas when compared with benign
melanocytic nevi, but with lesser frequency when compared
with metastatic melanomas [34, 35]. Thus, PTEN losses
appear to occur in later stages of melanomagenesis and may
contribute to the transformation of a benign melanocytic
proliferation into an invasive melanoma.
4. Ocular Melanoma
Melanomas of the eye are categorized as either con-
junctival or uveal, with the latter being further divided
between anterior uveal melanomas (iris) and posterior
uveal melanomas (ciliary and choroidal). Not surprisingly,
diﬀerences in the histopathology and/or clinical presentation
of these neoplasms exist, and the most striking distinction
is in prognosis [36, 37]. Melanomas of the conjunctiva
and iris have relatively good outcomes, while survival rates
of those with posterior uveal melanoma markedly decline.
Speciﬁcally, the 5-year mortality rate due to metastasis of
ciliary body or choroidal melanomas is approximately 30%,
compared to about 3% for iris melanomas [37]. Thus,
a greater urgency in exploring the molecular mechanisms of
posterior uveal melanomagenesis in the hopes of developing
new and eﬀective therapies is understandable.
5. Uveal Melanoma
The identiﬁcation of susceptibility genes through linkage
analysis has not proved fruitful due to the low occurrence of
uveal melanoma in the familial setting. Furthermore, while
CDKN2A is implicated in 25–40% of familial cutaneous
melanomas, the germline mutation infrequently occurs in
therareuvealmelanoma-pronefamiliesstudied[38].Finally,
data implicating the protooncogenes NRAS and BRAF is not
as convincing in uveal melanomagenesis as it is in sporadic
cutaneous melanomagenesis [39–41]. Nonetheless, evidence
for the constitutive activation of the MAPK pathway in
uvealmelanomaexists,suggestinginvolvementofadisparate
protooncogene [41].
5.1. GNAQ. Screening of potential oncogenes that may acti-
vatetheMAPKpathwayhasledtothediscoveryofmutations
in GNAQ, a stimulatory αq subunit of heterotrimeric G pro-
teins (Gαβγ)[ 42–44]. Upon the binding of an extracellular
signal molecule to a G-protein-coupled receptor on the cell
surface, GDP bound to the Gα subunit of Gαβγ is replaced
with GTP, allowing for the dissociation of Gα from Gβγ.N o
longer tethered to Gβγ,G αq stimulates phospholipase Cβ,
until its intrinsic GTPase activity renders it unable to doPathology Research International 5
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Figure 3: Timeline highlighting pivotal discoveries of key molecular players discussed in this paper on melanomagenesis.
so. Phospholipase Cβ hydrolyzes phosphatidylinositol 4,5-
bisphosphonate (PIP2) into two second messengers: inositol
1,4,5-triphosphate(IP3)anddiacylglycerol(DAG).IP3func-
tionstoincreasecytosolcalciumlevelsbyreleasingthecation
from endoplasmic reticulum stores. Calcium then activates
conventionalisoformsoftheserine/threoninekinase,protein
kinase C, while DAG activates both conventional and novel
isoforms of the kinase. Finally, protein kinase C stimulates
the RAF/MEK/ERK pathway, which induces several prolifer-
ative and survival processes, as discussed above.
Mutation of GNAQ at codon 209 prevents the hydrolysis
of GTP and locks GNAQ in its active, GTP-bound state.
ConstitutiveactivationofGNAQistantamounttooncogenic
activation of the MAPK cascade and accounts for approx-
imately 50% of uveal melanomas [43]. While inhibitors of
GNAQ, phospholipase Cβ, or protein kinase C isoforms have
yet to be developed, small, preliminary studies involving the
downstream inhibition of MEK have encouraged investiga-
tion through formal clinical trials [45]. The results of these
larger studies may oﬀer much needed hope to those aﬄicted
with this aggressive disease.
6. Conclusion
Many of the pivotal discoveries regarding the key molecular
playersdiscussedinthispaperarehighlightedonthetimeline
pictured in Figure 3 [22, 42, 46–50]. While much progress
has been made in unlocking the mysteries surrounding
the molecular pathogenesis of cutaneous melanoma, the
story is far from complete. Just as researchers are begin-
ning to understand the mechanisms by which activating
mutations in the RAS and RAF protooncogenes lead to
proliferative and antiapoptotic eﬀects, evidence is mount-
ing for the role of constitutive MAPK activity in tumor
evasion of immune surveillance, suppression of immune
response, tumor angiogenesis, and metastatic dissemination
[51–62]. Furthermore, approximately 40% of melanoma
kindreds harbor CDKN2A mutations, and signiﬁcantly less
perpetuate CDK4 mutations, thus the genetic basis of
a substantial proportion of cases of familial cutaneous
melanoma clearly remains unresolved [7, 63]. Genome-
wide association studies have enabled the identiﬁcation of
several low-penetrance, high-frequency susceptibility genes
[64, 65]. Analyses of these genes will likely reveal additional
molecularpathwaysinvolvedinmelanomaformationand/or
progression.
While the battle against uveal melanoma may not be as
far along as that against its cutaneous counterpart, lines have
been drawn in the sand, and war is under way. In addition
to taking aim at the constitutive activation of the MAPK
pathway, researchers have discovered potential targets in the
PI3/AKTandinsulingrowthfactor(IGF)signalingpathways,
mTOR,protooncogenec-MET,andtumor-suppressorbreast
cancer-1 (BRCA1)-associated protein-1 (BAP1), early onset
[43]. While clinical trials are under way to determine if
aberrations in the aforementioned molecules and pathways
can be manipulated to stiﬂe and/or reverse uveal melanoma-
genesis, the need for intervention at more than just one
critical junction will likely be needed.
Despite the plethora of questions that remain, the poten-
tialofthisearlyresearchtobeneﬁtdisease-strickenpatientsis
already being realized. Preliminary studies employing selec-
tive inhibitors against key players detailed in the aforemen-
tioned discussion have demonstrated encouraging results
[43,66,67].Whethertheseparticulartreatmentsproveeﬀec-
tive in rigorous clinical trials remains to be seen. Regardless,
researchers are reassured in seeking a molecular basis for the
treatment of melanoma.6 Pathology Research International
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